LIDDS is a company built on research and development. The company has developed a unique drug delivery technology, which has been utilized in the generation of an oncology pipeline of in-house and partnered programs from early to late stage development. The pipeline represents LIDDS ambition to develop better and safer treatments for patients that have a strong value to global pharma companies. This is done by maximizing the efficacy by efficient targeting of diseased part of the body while minimizing off-target accumulation to avoid systemic side effects.
Liproca Depot is being developed for prostate cancer. Liproca Depot is NanoZolid-formulated 2-hydroxyflutamide (2-HOF) which is an anti-androgen drug. 2-HOF is normally being used systemically for treating prostate cancer patients before radical treatments, but often with severe side-effects. These can be avoided with local administration of Liproca Depot in the tumor.
Nanodotax is NanoZolid-formulated docetaxel which is a commonly used chemotherapeutic drug that has been approved for several oncological conditions. Nanodotax has shown to be safe and well tolerated in a phase I study. In addition there was an observed effect on systemic and local immunological biomarkers indicating that the immune system was responding positively and specifically to the treatment.
Nanoimod is the toll-like receptor 9 (TLR9) agonist agatolimod formulated in NanoZolid®. The project is in preclinical development and is being prepared for a Phase Ib clinical study in multiple cancer indications in addition to treatment with Checkpoint inhibitors.
LIDDS has entered into a research and development agreement with Johnson & Johnson Enterprise Innovation Incorporated and a license agreement for China with Puheng Pharma for Liproca Depot.